Two recent phase III clinical trials used COX2 inhibitors in combination with platinum-based chemotherapy failed to demonstrate a survival benefit due to “unselected” advanced NSCLC patients in a randomized phase III trial [32]. Here, PTGS2 is linked to non-small cell lung carcinoma.